398 related articles for article (PubMed ID: 28933735)
1. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.
Khan M; Cortes J; Kadia T; Naqvi K; Brandt M; Pierce S; Patel KP; Borthakur G; Ravandi F; Konopleva M; Kornblau S; Kantarjian H; Bhalla K; DiNardo CD
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933735
[TBL] [Abstract][Full Text] [Related]
2. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.
Paschka P; Schlenk RF; Gaidzik VI; Herzig JK; Aulitzky T; Bullinger L; Späth D; Teleanu V; Kündgen A; Köhne CH; Brossart P; Held G; Horst HA; Ringhoffer M; Götze K; Nachbaur D; Kindler T; Heuser M; Thol F; Ganser A; Döhner H; Döhner K
Haematologica; 2015 Mar; 100(3):324-30. PubMed ID: 25596267
[TBL] [Abstract][Full Text] [Related]
3. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
[No Abstract] [Full Text] [Related]
4. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
[TBL] [Abstract][Full Text] [Related]
5. Frequency and Clinicopathologic Features of RUNX1 Mutations in Patients With Acute Myeloid Leukemia Not Otherwise Specified.
You E; Cho YU; Jang S; Seo EJ; Lee JH; Lee JH; Lee KH; Koh KN; Im HJ; Seo JJ; Park YM; Lee JK; Park CJ
Am J Clin Pathol; 2017 Jul; 148(1):64-72. PubMed ID: 28927163
[TBL] [Abstract][Full Text] [Related]
6. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
[TBL] [Abstract][Full Text] [Related]
7. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
Venugopal S; DiNardo CD; Loghavi S; Qiao W; Ravandi F; Konopleva M; Kadia T; Bhalla K; Jabbour E; Issa GC; Macaron W; Daver N; Borthakur G; Montalban-Bravo G; Yilmaz M; Patel KP; Kanagal-Shamanna R; Chien K; Maiti A; Kantarjian H; Short NJ
Am J Hematol; 2022 Dec; 97(12):1560-1567. PubMed ID: 36087091
[TBL] [Abstract][Full Text] [Related]
8. AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients.
Alpermann T; Haferlach C; Eder C; Nadarajah N; Meggendorfer M; Kern W; Haferlach T; Schnittger S
Leuk Res; 2015 Mar; 39(3):265-72. PubMed ID: 25592059
[TBL] [Abstract][Full Text] [Related]
9. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation.
Kuo MC; Liang DC; Huang CF; Shih YS; Wu JH; Lin TL; Shih LY
Leukemia; 2009 Aug; 23(8):1426-31. PubMed ID: 19282830
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.
Devillier R; Gelsi-Boyer V; Brecqueville M; Carbuccia N; Murati A; Vey N; Birnbaum D; Mozziconacci MJ
Am J Hematol; 2012 Jul; 87(7):659-62. PubMed ID: 22535592
[TBL] [Abstract][Full Text] [Related]
11. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
Gaidzik VI; Teleanu V; Papaemmanuil E; Weber D; Paschka P; Hahn J; Wallrabenstein T; Kolbinger B; Köhne CH; Horst HA; Brossart P; Held G; Kündgen A; Ringhoffer M; Götze K; Rummel M; Gerstung M; Campbell P; Kraus JM; Kestler HA; Thol F; Heuser M; Schlegelberger B; Ganser A; Bullinger L; Schlenk RF; Döhner K; Döhner H
Leukemia; 2016 Nov; 30(11):2160-2168. PubMed ID: 27137476
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
DiNardo CD; Rausch CR; Benton C; Kadia T; Jain N; Pemmaraju N; Daver N; Covert W; Marx KR; Mace M; Jabbour E; Cortes J; Garcia-Manero G; Ravandi F; Bhalla KN; Kantarjian H; Konopleva M
Am J Hematol; 2018 Mar; 93(3):401-407. PubMed ID: 29218851
[TBL] [Abstract][Full Text] [Related]
13. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
[TBL] [Abstract][Full Text] [Related]
14. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.
Schnittger S; Eder C; Jeromin S; Alpermann T; Fasan A; Grossmann V; Kohlmann A; Illig T; Klopp N; Wichmann HE; Kreuzer KA; Schmid C; Staib P; Peceny R; Schmitz N; Kern W; Haferlach C; Haferlach T
Leukemia; 2013 Jan; 27(1):82-91. PubMed ID: 23018865
[TBL] [Abstract][Full Text] [Related]
15. [The prognostic value of cloned genetic mutations detected by second-generation sequencing in RUNX1-RUNX1T1 positive acute myeloid leukemia patients receiving intensive consolidation therapy].
Yu JQ; Xue SL; Li Z; Wang J; Wang C; Chu XL; Han R; Tao T; Qiu QC; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):210-215. PubMed ID: 32311890
[No Abstract] [Full Text] [Related]
16. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of RUNX1 Gene Mutation in Patients with Myelodysplastic Syndrome].
Cai XH; Chen MY; Chao HY; Jiang NK; Lu XZ; Han WM; Qin W; Jia ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):202-208. PubMed ID: 32027277
[TBL] [Abstract][Full Text] [Related]
18. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
19. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
Badar T; Patel KP; Thompson PA; DiNardo C; Takahashi K; Cabrero M; Borthakur G; Cortes J; Konopleva M; Kadia T; Bohannan Z; Pierce S; Jabbour EJ; Ravandi F; Daver N; Luthra R; Kantarjian H; Garcia-Manero G
Leuk Res; 2015 Dec; 39(12):1367-74. PubMed ID: 26547258
[TBL] [Abstract][Full Text] [Related]
20. [Clinical Characteristics of Acute Myeloid Leukemia Patients with RUNX1 Gene Mutation].
Ni ZF; Ma LJ; Shi LL; Shen PL; Zhao JQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1411-1416. PubMed ID: 34627418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
